Non-internalizing antibody–drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix

International Journal of Cancer

Volumn 140, Issue 7, 2017, Pages 1670-1679

  Gébleux, Rémy ^a   Stringhini, Marco ^a   Casanova, Ruben ^b   Soltermann, Alex ^b   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

A1 domain of tenascin C; antibody drug conjugates; IgG; MMAE; SIP; vascular targeting

Indexed keywords

ANTIBODY DRUG CONJUGATE; CATHEPSIN B; CITRULLINE; VALINE; VEDOTIN; ANTIBODY; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; ISOPROTEIN; MONOCLONAL ANTIBODY; OLIGOPEPTIDE; TENASCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RELEASE; DRUG STRUCTURE; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; MALIGNANT NEOPLASM; MDA-MB-231 CELL LINE; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; SINGLE DRUG DOSE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CHO CELL LINE; CRICETULUS; ENDOTHELIUM; FLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHO CELLS; CITRULLINE; CRICETULUS; ENDOTHELIUM; EXTRACELLULAR MATRIX; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, FLUORESCENCE; OLIGOPEPTIDES; PROTEIN ISOFORMS; TENASCIN; VALINE;

EID: 85007500664     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30569     Document Type: Article

References (50)

1. Bosslet K, Straub R, Blumrich M, et al. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 1998;58:1195–201.
2. van der Veldt AAM, Hendrikse NH, Smit EF, et al. Biodistribution and radiation dosimetry of C-11-labelled docetaxel in cancer patients. Eur J Nucl Med Mol Imag 2010;37:1950–8.
3. van der Veldt AAM, Lubberink M, Mathijssen RHJ, et al. Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using C-11 docetaxel and Positron Emission Tomography. Clin Cancer Res 2013;19:4163–73.
4. Krall N, Scheuermann J, Neri D. Small targeted cytotoxics: current state and promises from dna-encoded chemical libraries. Angew Chem Int Ed Engl 2013;52:1384–402.
5. Gerber HP, Senter PD, Grewal IS. Antibody drug-conjugates targeting the tumor vasculature: current and future developments. MAbs 2009;1:247–53.
6. Teicher BA, Chari RVJ. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011;17:6389–97.
7. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013;64:15–29.
8. Chari RVJ, Miller ML, Widdison WC. Antibody- drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl 2014;53:3796–827.
9. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631–7.
10. Ballantyne A, Dhillon S. Trastuzumab emtansine: first global approval. Drugs 2013;73:755–65.
11. Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009;69:2358–64.
12. Matsumura Y. Cancer stromal targeting (CAST) therapy. Adv Drug Del Rev 2012;64:710–9.
13. Yasunaga M, Manabe S, Tarin D, et al. Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. Bioconjug Chem 2011;22:1776–83.
14. Yasunaga M, Manabe S, Matsumura Y. New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots. Cancer Sci 2011;102:1396–402.
15. Bernardes GJL, Casi G, Truessel S, et al. A traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem Int Ed Engl 2012;51:941–4.
16. Perrino E, Steiner M, Krall N, et al. Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res 2014;74:2569–78.
17. Gebleux R, Wulhfard S, Casi G, et al. Antibody format and drug release rate determine the therapeutic activity of noninternalizing antibody-drug conjugates. Mol Cancer Ther 2015;14:2606–12.
18. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436–46.
19. Casi G, Neri D. Antibody-drug conjugates and small molecule-drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents. J Med Chem 2015;58:8751–61.
20. Casi G, Neri D. Noninternalizing targeted cytotoxics for cancer therapy. Mol Pharm 2015;12:1880–4.
21. Doronina SO, Bovee TD, Meyer DW, et al. Novel peptide linkers for highly potent antibody-auristatin. Conjug Bioconjug Chem 2008;19:1960–3.
22. Dubowchik GM, Firestone RA, Padilla L, et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjugate Chem 2002;13:855–69.
23. Sutherland MSK, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006;281:10540–7.
24. Paganelli G, Grana C, Chinol M, et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999;26:348–57.
25. Riva P, Franceschi G, Frattarelli M, et al. I-131 radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma—phase I and II study. Acta Oncol 1999;38:351–9.
26. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;20:1389–97.
27. Brack SS, Silacci M, Birchler M, et al. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006;12:3200–8.
28. Heuveling DA, de Bree R, Vugts DJ, et al. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. J Nucl Med 2013;54:397–401.
29. Aloj L, D'Ambrosio L, Aurilio M, et al. Radioimmunotherapy with Tenarad, a I-131-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. Eur J Nucl Med Mol Imag 2014;41:867–77.
30. Schwager K, Villa A, Rosli C, et al. A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Head Neck Oncol 2011;3:25
31. Schliemann C, Wiedmer A, Pedretti M, et al. Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leukemia Res 2009;33:1718–22.
32. Gutbrodt KL, Schliemann C, Giovannoni L, et al. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med 2013;5.
33. Li EQ, Pedraza A, Bestagno M, et al. Mammalian cell expression of dimeric small immune proteins (SIP). Protein Eng 1997; 10:731–6.
34. Borsi L, Balza E, Bestagno M, et al. Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002;102:75–85.
35. McDonagh CF, Turcott E, Westendorf L, et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 2006;19:299–307.
36. Zuberbuhler K, Palumbo A, Bacci C, et al. A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cells. Protein Eng Des Sel 2009;22:169–74.
37. Pasche N, Woytschak J, Wulhfard S, et al. Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7. J Biotechnol 2011;154:84–92.
38. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77.
39. Junker K, Thomas M, Schulmann K, et al. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 1997;123:469–77.
40. Shen BQ, Xu KY, Liu LN, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012;30:184–9.
41. Dorywalska M, Strop P, Melton-Witt JA, et al. Effect of attachment site on stability of cleavable antibody drug conjugates. Bioconjug Chem 2015;26:650–9.
42. Dorywalska M, Dushin R, Moine L, et al. Molecular basis of valine-citrulline-PABC linker instability in site-specific ADCs and its mitigation by linker design. Mol Cancer Ther 2016;15:958–70.
43. Dennis MS, Jin HK, Dugger D, et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 2007;67:254–61.
44. El Emir E, Qureshi U, Dearling JLJ, et al. Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas. Cancer Res 2007;67:11896–905.
45. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002;71:907–20.
46. Knowles SM, Wu AM. Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol 2012;30:3884–92.
47. Krall N, Pretto F, Decurtins W, et al. A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors. Angew Chem Int Ed Engl 2014;53:4231–5.
48. Ishima Y, Chen D, Fang J, et al. S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects. Bioconjug Chem 2012;23:264–71.
49. Duncan R, Sat-Klopsch YN, Burger AM, et al. Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate. Cancer Chemother Pharmacol 2013;72:417–27.
50. Shiah JJ, Sun Y, Peterson CM, et al. Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J Control Release 1999;61:145–57.